IRIS
NUVOLONE, MARIO ULISSE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.603
AS - Asia 2.844
EU - Europa 2.027
SA - Sud America 448
Continente sconosciuto - Info sul continente non disponibili 208
AF - Africa 183
OC - Oceania 6
Totale 10.319
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.395
CN - Cina 1.041
SG - Singapore 694
IE - Irlanda 510
HK - Hong Kong 374
VN - Vietnam 344
IT - Italia 336
BR - Brasile 334
RU - Federazione Russa 284
DE - Germania 213
FI - Finlandia 155
FR - Francia 143
ZA - Sudafrica 141
GB - Regno Unito 104
CA - Canada 93
BD - Bangladesh 75
IN - India 71
UA - Ucraina 61
AR - Argentina 44
MX - Messico 33
ES - Italia 32
IQ - Iraq 29
SE - Svezia 29
PL - Polonia 28
JP - Giappone 27
TR - Turchia 24
NL - Olanda 23
CO - Colombia 19
PK - Pakistan 19
AT - Austria 17
BE - Belgio 16
SA - Arabia Saudita 16
ID - Indonesia 15
IL - Israele 15
EC - Ecuador 13
GP - Guadalupe 13
HN - Honduras 13
NI - Nicaragua 12
VE - Venezuela 12
LT - Lituania 11
CR - Costa Rica 10
PT - Portogallo 10
JO - Giordania 9
LB - Libano 9
PH - Filippine 9
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
JM - Giamaica 8
MA - Marocco 8
AL - Albania 7
SC - Seychelles 7
UY - Uruguay 7
CH - Svizzera 6
CL - Cile 6
DK - Danimarca 6
EG - Egitto 6
MY - Malesia 6
PY - Paraguay 6
TN - Tunisia 6
AU - Australia 5
AZ - Azerbaigian 5
BG - Bulgaria 5
GT - Guatemala 5
KE - Kenya 5
TH - Thailandia 5
IR - Iran 4
KR - Corea 4
NO - Norvegia 4
PR - Porto Rico 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
AM - Armenia 3
BH - Bahrain 3
BN - Brunei Darussalam 3
BO - Bolivia 3
CW - ???statistics.table.value.countryCode.CW??? 3
CZ - Repubblica Ceca 3
HR - Croazia 3
NP - Nepal 3
PE - Perù 3
CY - Cipro 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GA - Gabon 2
GE - Georgia 2
GR - Grecia 2
HT - Haiti 2
KZ - Kazakistan 2
LU - Lussemburgo 2
LV - Lettonia 2
MK - Macedonia 2
MN - Mongolia 2
MU - Mauritius 2
NG - Nigeria 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
Totale 10.090
Salva come PNG Salva come JPEG
Città #
San Jose 561
Dublin 510
Ashburn 387
Singapore 382
Hong Kong 363
Chandler 349
Council Bluffs 294
Dallas 289
Beijing 247
Nanjing 158
Boardman 138
Johannesburg 128
Los Angeles 119
Ho Chi Minh City 106
Lauterbourg 101
Helsinki 96
Jacksonville 96
Hanoi 93
New York 82
Princeton 75
Lawrence 68
Munich 58
Wilmington 57
Medford 53
Nanchang 53
Ann Arbor 52
Buffalo 52
Santa Clara 52
Redondo Beach 50
Shanghai 48
São Paulo 43
Milan 42
Shenyang 42
Orem 41
Jiaxing 38
Moscow 36
Pavia 36
Hebei 35
Changsha 34
Hangzhou 31
Rome 28
Atlanta 26
Tianjin 24
Warsaw 24
Frankfurt am Main 23
Phoenix 23
Tokyo 23
Denver 22
Montreal 22
London 20
Naples 20
Da Nang 19
Chicago 18
Nuremberg 18
San Francisco 18
The Dalles 18
Toronto 18
Brooklyn 17
Columbus 17
Haiphong 17
Seattle 17
Woodbridge 17
Norwalk 16
Poplar 16
Turku 16
Brussels 15
Mexico City 15
Redwood City 15
Chennai 14
Falkenstein 14
Palermo 13
Piscataway 13
Washington 13
Charlotte 12
Managua 12
North Bergen 12
Ankara 11
Brasília 11
Stockholm 11
Baghdad 10
Houston 10
San José 10
Amman 9
Amsterdam 9
Belo Horizonte 9
Fairfield 9
Hải Dương 9
Newark 9
Rio de Janeiro 9
Riyadh 9
Turin 9
Biên Hòa 8
Curitiba 8
Philadelphia 8
Richmond 8
Beirut 7
Bologna 7
Boston 7
Catania 7
City of London 7
Totale 6.351
Salva come PNG Salva come JPEG
Nome #
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 232
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 169
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 150
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 142
Identification of genes for normalization of RT-qPCR gene expression data: A review of published literature 135
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 135
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 134
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 133
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 132
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 131
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 130
Bone marrow amyloidosis. 128
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 126
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 125
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 125
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 123
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 122
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 121
Prognostication of survival and progression to dialysis in AA amyloidosis 120
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 118
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 118
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 112
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 112
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 111
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 111
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 111
Altered monoaminergic systems and depressive-like behavior in congenic prion protein knock-out mice 111
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 111
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 109
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 106
A case of monoclonal gammopathy of renal significance 106
Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis 105
Development and Validation of Staging Systems for AA Amyloidosis 102
Amyloid diseases at the molecular level: general overview and focus on AL amyloidosis. 102
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 102
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 101
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 98
Cystatin F is a biomarker of prion pathogenesis in mice 97
Regulated expression of amyloidogenic immunoglobulin light chains in mice 97
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients 95
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis 95
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 93
Prion pathogenesis in the absence of NLRP3/ASC inflammasomes 93
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 91
Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses 89
The complex PrPc-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease 88
The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6 88
Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier 88
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 86
Extended characterization of the novel co-isogenic C57BL/6J Prnp−/− mouse line 86
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 86
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy 85
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development 85
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 85
A neuroprotective role for microglia in prion diseases 85
Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis 85
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 84
Prion protein and Ab-related synaptic toxicity impairment 84
Cells and prions: A license to replicate 84
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 84
Genome-wide transcriptomics identifies an early preclinical signature of prion infection 84
Efficient amyloid A clearance in the absence of immunoglobulins and complement factors 83
The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis 82
Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture 82
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 81
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 81
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 79
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 79
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 79
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 79
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis 78
Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney 78
Structure-based drug design identifies polythiophenes as antiprion compounds 77
Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation 76
Brain aging is faithfully modelled in organotypic brain slices and accelerated by prions 73
Prion diseases disrupt glutamate/glutamine metabolism in skeletal muscle 72
SMaRT M-Seq: an optimized step-by-step protocol for M protein sequencing in monoclonal gammopathies 71
Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling 71
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 69
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 69
The Role of the NADPH Oxidase NOX2 in Prion Pathogenesis 69
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 68
Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis 65
Systemic amyloidosis: novel therapies and role of biomarkers 65
Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science 65
The workings of the amyloid diseases. 65
SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells 64
Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice 64
Analysis of co-isogenic prion protein deficient mice reveals behavioral deficits, learning impairment, and enhanced hippocampal excitability 64
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 63
Glial activation in prion diseases is selectively triggered by neuronal PrPSc 62
Tau Exon 10 Inclusion by PrPC through Downregulating GSK3β Activity 62
Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression 62
The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis 62
The ASC inflammasome adapter governs SAA-derived protein aggregation in inflammatory amyloidosis 61
Author Correction: The dengue-specific immune response and antibody identification with machine learning 61
The Priority position paper: Protecting Europe's food chain from prions 60
Management of the elderly patient with AL amyloidosis 59
The immunobiology of prion diseases 58
A novel transthyretin variant p.Val114Glu (Val94Glu) in an Italian patient with mixed phenotype hereditary transthyretin amyloidosis 57
Totale 9.391
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.859
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.859
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022269 0 0 0 0 8 9 6 26 20 5 40 155
2022/20231.175 119 89 20 66 92 104 25 51 563 6 29 11
2023/2024471 59 103 25 28 46 102 16 26 6 18 22 20
2024/20251.541 28 110 12 37 17 119 94 97 401 69 187 370
2025/20264.350 283 271 371 507 606 157 795 271 472 284 134 199
2026/20271.500 200 240 311 479 270 0 0 0 0 0 0 0
Totale 10.319